NodThera is developing a portfolio of novel, potent and selective NLRP3 inflammasome inhibitors, with one clinical-stage candidate and several others in preclinical development. The company is ...

Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01 ...